Development of immunoassays for anti-electronegative LDL autoantibodies and immune complexes  by Faulin, Tanize do Espirito Santo et al.
Clinica Chimica Acta 413 (2012) 291–297
Contents lists available at SciVerse ScienceDirect
Clinica Chimica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /c l inch imDevelopment of immunoassays for anti-electronegative LDL autoantibodies
and immune complexes
Tanize do Espirito Santo Faulin, Karine Cavalcanti Maurício de Sena-Evangelista, Débora Bezerra Pacheco,
Elaine Moura Augusto, Dulcineia Saes Parra Abdalla ⁎
Faculty of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, B17, São Paulo, SP, 05508-900, Brazil⁎ Corresponding author at: Av. Prof. Lineu Prestes,
05508-900, Brazil. Tel.: +55 11 3091 3637; fax: +55 1
E-mail address: dspa@usp.br (D.S.P. Abdalla).
0009-8981 © 2011 Elsevier B.V.
doi:10.1016/j.cca.2011.10.004
Open access under the Elsa b s t r a c ta r t i c l e i n f oArticle history:
Received 20 July 2011
Received in revised form 5 October 2011
Accepted 6 October 2011
Available online 18 October 2011
Keywords:
Atherosclerosis
ELISA
Electronegative LDL
Monoclonal antibody
Background: Electronegative low-density lipoprotein (LDL−) promotes atherosclerosis through inﬂammato-
ry and immunologic mechanisms that lead to the production of anti-LDL(−) autoantibodies and to the sub-
sequent formation of immune complexes (IC) and macrophage foam cells. We described the development
and validation of an ELISA for the quantiﬁcation of free anti-LDL(−) autoantibodies and an ELISA for the
quantiﬁcation of IC consisting of LDL(−)-bound IgG in human plasma.
Methods: LDL(−) puriﬁed from human plasma, and anti-LDL(−) monoclonal antibody Fab fragments were
adsorbed onto ELISA plates to capture anti-LDL(−) autoantibodies and IC-LDL(−), respectively. The perfor-
mance characteristics of both ELISAs, including the limits of detection and quantiﬁcation, accuracy and inter-
and intra-assay precision were evaluated. Linearity, interference and stability tests were also performed.
Results: The calibration range of the anti-LDL(−) assay was 0.004–0.125 mU/l and plasma demonstrated a
dilutional linearity when diluted 1:100, 1:200, 1:400 and 1:800. The calibration range of the IC-LDL(−)
assay was 0.06–4 U/l, and plasma demonstrated a dilutional linearity when diluted 1:12.5, 1:25, 1:50 and
1:100. Both ELISAs showed intra- and inter-assay precision and recovery within the required limits for im-
munoassays.
Conclusion: These ELISAs can be used in clinical studies and for the biochemical investigation of atherosclero-
sis. In addition, they will enable the comprehensive evaluation of the importance of bound or free autoanti-
bodies against LDL(−) in this disease.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Atherosclerosis is a multifactorial chronic inﬂammatory disease
characterized by the accumulation of lipids, monocytes/macrophages,
lymphocytes, smooth muscle cells and extracellular matrix in the inti-
ma layer of large arteries [1]. Multiple antigenic stimuli have been asso-
ciatedwith the pathogenesis of atherosclerosis [2].Most of these stimuli
come from modiﬁed self-antigens, such as modiﬁed low-density lipo-
protein (LDL) that is targeted by both the innate and adaptive immune
responses [3]. A number of complex biochemical reactions are involved
in themodiﬁcation of LDL particles that lead to a sequential formation of
many novel epitopes during the modiﬁcation process [4].
Electronegative LDL (LDL−) is a minimally modiﬁed form of LDL
that is present in plasma [5] and has proinﬂammatory [6] and
proatherogenic [7] properties. Furthermore, LDL(−) is immunogenic
because autoantibodies to speciﬁc epitopes of LDL(−) have been
detected in human plasma [8–10]. LDL(−) has a direct proatherogenic580-Bloco 17, São Paulo, SP,
1 3813 2197.
evier OA license.effect, and lipoprotein modiﬁcation also results in an immune response
directed against the neoepitopes. LDL(−) promotes atherosclerosis
through inﬂammatory and immunologic mechanisms that lead to the
production of anti-LDL(−) autoantibodies and subsequently to the for-
mation of immune complexes (IC) andmacrophage foam cells [11]. The
involvement of LDL-IC in the pathogenesis of atherosclerosis was dem-
onstrated by the studies of Lopes-Virella and co-workers. These authors
showed that the incubation of human monocyte-derived macrophages
with insoluble LDL-containing IC prepared with human native LDL and
rabbit anti-LDL antibodies efﬁciently induces in vitro foam cell forma-
tion [12,13]. Inﬂammatory and immune reactions are widely recog-
nized as an integral part of the pathogenesis of atherosclerotic lesions,
Therefore, it is important to employ validated analytical methods to ob-
tain reliable results that can be properly interpreted in clinical studies.
2. Materials and methods
2.1. LDL(−) isolation
The use of human plasma was approved by the Ethics Committee
in human research of the University of Sao Paulo. LDL(−) was isolat-
ed according to methods previously described [14], with minor
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percholesterolemic donors by sequential preparative ultracentrifuga-
tion at 4 °C between the densities of 1.019 and 1.063 g/ml. The LDL
was applied to an ion exchange column (Sepharose UNO Q12, Bio-
Rad Laboratories Inc, Hercules, CA) to separate LDL(−) and native
LDL subfractions using fast protein liquid chromatography (FPLC;
Bio-Rad). The isolated LDL(−) fraction was dialyzed against phos-
phate buffered saline (PBS) and concentrated using a concentrator de-
vice (Vivaspin 20, 100,000 MWCO, GE Healthcare, Uppsala, Sweden).
To avoid Lp(a) contamination, the levels of Lp(a) were determined
by nephelometry and were not detectable.
LDL(−) isolation was conﬁrmed by 0.5% agarose gel electrophore-
sis; 10 μg of LDL(−) or native LDL protein was applied per well, and
electrophoresis was carried out at 60 V for 2 h. The gel was stained
in 0.5% Coomassie Brilliant Blue G that was dissolved in an ethanol–
acetic acid–watermixture (10:30:60, vol:vol:vol). The electrophoretic
mobility of LDL(−) was compared to the electrophoretic mobility of
native LDL. This puriﬁed LDL(−) was adsorbed on ELISA plates for
the anti-LDL(−) autoantibody assays.
2.2. Production and digestion of anti-LDL(−) monoclonal antibody
All procedures involving animals were approved by the Commission
of Ethics in animal experimentation of the University of Sao Paulo. Pre-
viously, we described the production of hybridoma cells that secrete the
2C7D5F10 monoclonal antibody (MAb) against LDL(−) by immuniza-
tion of Balb/c mice [14]. Male isogenic Balb/c mice at 8 weeks of age re-
ceived an intraperitoneal injection of 0.5 ml of culture medium
containing 2×106 hybridoma cells secreting anti-LDL(−) MAb. After
7 days, the ascitic ﬂuid containing anti-LDL(−) MAb was collected
and puriﬁed on a protein G Sepharose column (GE Healthcare, Uppsala,
Sweden). The concentration of MAb was determined by UV absorption
at 280 nm(BeckmanDU640 spectrophotometer, Beckman Instruments,
Fullerton, CA), using a molar extinction coefﬁcient of 1.3 l/mol cm. This
puriﬁed 2C7D5F10 MAb was used as a standard in the ELISAs for the
quantiﬁcation of anti-LDL(−) autoantibodies.
Papain (Sigma Chemical Co, St. Louis, MO)was used to produce the
Fab (fragment antigen binding) fragments of the 2C7D5F10 MAb. The
2C7D5F10 MAb (10 mg) was digested in a solution containing 1 mg
papain, 3 mmol/l EDTA and 10 mmol/l cysteine hydrochloride in
100 mmol/l sodium acetate, pH 5.5. The mixture was incubated, with
gentle stirring, at 37 °C for 4 h. The reaction was stopped by the addi-
tion of 30 mmol/l iodoacetamide [15]. The product was dialyzed
against PBS (pH 7.4) and applied to a protein G Sepharose column.
Fab fragments passed freely through the column, whereas undigested
IgG and Fc fragments were retained in the column and eluted with
0.1 mol/l citric acid buffer (pH 3.0). The collected fractions were neu-
tralized with 1 mol/l Tris–HCl buffer (pH 9.0). Fab digestion was con-
ﬁrmed by comparison to the whole MAb after separation by reducing
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) [16] followed by silver staining of the gel [17]. The puriﬁed
2C7D5F10 Fab was adsorbed on ELISA plates for the assay of immune
complexes.
2.3. Development of ELISA assays
The basic enzyme immunoassay protocol was used with variation
in each step to select for optimal LDL(−) or antibody concentration,
to choose an appropriate assay buffer, to determine the best dilution
of plasma and to reduce nonspeciﬁc interferences.
2.3.1. Anti-LDL(−) autoantibody ELISA methodology
The wells of 96-well ﬂat bottom polystyrene plates (Costar, Corning
Inc., NY) were coated with 1 μg/ml of LDL(−) in 50 μl 0.05 mol/l
carbonate-bicarbonate buffer (pH 9.6) and were incubated overnight
at 4 °C. The plates were washed three times with PBS (pH 7.4)containing 0.05% Tween 20 (200 μl/well) using a plate washer (Ultra-
wash Plus, Dynex Technologies, Chantilly, VA). Free binding sites were
blocked by the addition of 150 μl/well of PBS containing 2% nonfat dry
milk (previously inactivated by heating to 100 °C), and 0.01% Tween
20, for 90 min at 37 °C. The blocking was followed by a washing step
as described above. Standards or plasma samples diluted 1:400 in PBS
containing 1% non-fat milk and 0.01% Tween 20 were added to the
plates (50 μl/well) and incubated for 90 min at 37 °C. The plates were
washed and incubated with anti-human IgG-conjugated to horseradish
peroxidase (Bio-Rad) (diluted 1:2500) for 1 h at 37 °C. The reactivity of
the peroxidase was measured on washed plates by incubating with
50 μl of 3,3′,5,5′ tetramethylbenzidine (TMB, Sigma) for 10 min at
37 °C. The reaction was stopped by adding 0.5 mol/l sulfuric acid and
the absorbance at 450 nm was measured spectrophotometrically,
using a plate reader (SLT Spectra, Milan, Italy).2.3.1.1. Standard curve. Six concentrations of whole 2C7D5F10 MAb
(0.004, 0.008, 0.016, 0.031, 0.063 and 0.125 mU/l) were used as stan-
dards and were prepared in triplicate. Calibration curves were deter-
mined by plotting the concentrations of 2C7D5F10 MAb in the
working standard dilutions against the absorbance, in accordance
with the following equation: y=a×X+b, where y is the absorbance
at 450 nm, X is the concentration in log10 of anti-LDL(−) and a and b
are the calibration slope and intercept, respectively.2.3.2. Immune complexes of LDL(−): ELISA methodology
The wells of 96-well ﬂat bottom polystyrene plates (Costar) were
coated with 5 μg/ml of 2C7D5F10 MAb Fab (50 μl/well) in 0.05 mol/l
carbonate–bicarbonate buffer (pH 9.6) and were incubated overnight
at 4 °C. The plates were washed ﬁve timeswith PBS (pH 7.4) containing
0.05% Tween 20 (200 μl/well) using a plate washer (Ultrawash Plus,
Dynex Technologies, Chantilly, VA) and a 1 min soaking step was in-
cluded during the ﬁfth wash. Free binding sites were blocked by the ad-
dition of PBS (150 μl/well) containing 5% nonfat dry milk (previously
inactivated by heating to 100 °C) and 0.01% Tween 20 for 90 min at
37 °C. The blocking was followed by a washing step as described
above. Standards or plasma samples diluted 1:50 in PBS containing 1%
non-fat milk and 0.01% Tween 20 were added (50 μl/well) to the wells
and the plates were incubated for 90 min at 37 °C. The plates were
washed and were incubated with anti-human IgG (Fc speciﬁc) conju-
gated to horseradish peroxidase (Sigma) (diluted 1:4000) for 1 h at
37 °C. The reactivity of peroxidase was measured by incubating the
washed plateswith 50 μl of TMB for 15 min at 37 °C. Color development
was stopped by the addition of 0.5 mol/l sulfuric acid (50 μl/well), and
the absorbance at 450 nm was measured by spectrophotometry, using
a plate reader (SLT Spectra, Milan, Italy).2.3.2.1. Standard curve. Venous blood was collected from healthy vol-
unteers (without autoimmune diseases, diabetes, cardiovascular or
kidney diseases) into tubes containing ethylenediamine tetraacetic
acid (EDTA, 1 mg/ml blood). Plasma was separated by centrifugation
of the blood at 1500 g for 10 min at 4 °C. PMSF (1 mmol/l), 2 mmol/l
benzamidine, 2 μg/ml aprotinine and 20 mmol/l butylated hydroxy-
toluene were added to prevent protease activity and oxidative reac-
tions. Total IgG concentration of the plasma pool was measured on
a Behring Nephelometer II analyzer (BN II, Dade Behring, Marburg,
Germany). Using this plasma pool as reference, seven concentrations
of total human IgG (0.06, 0.12, 0.25, 0.5, 1, 2 and 4 U/l of IgG) were
used as standards in triplicate. Calibration curves were determined
by plotting the concentrations of IgG in the working standard dilu-
tions against the absorbance, in accordance with the following equa-
tion: y=a×X+b, where y is the absorbance at 450 nm, X is the
concentration in log10 of IC-LDL(−)/IgG and a and b are the calibra-
tion slope and intercept, respectively.
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Fig. 1. Agarose gel electrophoresis. LDL(−) (lane 1) has an increased electrophoretic
migration compared to native LDL (lane 2).
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The assay performance characteristics investigated in the validation
process were the limit of detection, limit of quantiﬁcation, intra- and
inter-assay precision and accuracy (recovery). The assay was validated
according to criteria from the validation guides of analytical methods,
including EURACHEM [18], INMETRO [19] and Shah et al. [20].
The limits of detection (LOD) and quantiﬁcation (LOQ) of the anti-
LDL(−) ELISA were established using triplicates of a whole 2C7D5F10
MAb standard that was serially diluted up to 0.0002 mU/l. The limits
of detection (LOD) and quantiﬁcation (LOQ) of IC-LDL(−) ELISA were
established using triplicates of the reference plasma that was serially
diluted up to 0.002 U/l of IgG. The LOD was expressed as the analyte
concentration corresponding to the mean value of ten sample blanks
(M10B)+3SD of the sample blank (SDB), using the formula
LOD=M10B+3SDB. The LOQ was expressed as the analyte concentra-
tion corresponding to the mean value of ten sample blanks+10 SD of
the sample blank, using the formula LOQ=M10B+10SDB.
Precision is ameasure of the closeness of the results obtainedwhen
analyzing the same sample more than once and describes the spread
of the results. The assay variationwas examined using plasma samples
that contained anti-LDL(−) or IC-LDL(−) at 3 different concentrations
that represent the entire range of the standard curve (1 near the low
LOQ, 1 near the center, and 1 near the upper boundary of the standard
curve). Each concentration was assayed in ten replicate samples with-
in the plate for the evaluation of intra-assay precision. The same sam-
ples were tested in 4 replicates in 5 assays performed on 5 different
days for the evaluation of inter-assay precision. Precision was
expressed as the percent coefﬁcient of variation (CV%). The CV% of
intra- and inter-assay precision should be b20% for the LOQ and
b15% for the other concentrations.
Accuracy expresses the closeness of a result to a true value. Accu-
racy was determined by analyzing the recovery of anti-LDL(−) or IC-
LDL(−) in two plasma samples that were spiked with known concen-
trations of anti-LDL(−) or IC-LDL(−). The results were expressed as
the recovery percentage (R%) of the concentration found compared
to the target added concentrations. The recovery should be within
80 to 120% of the nominal concentration.
2.5. Dilutional linearity
Dilutional linearity was assessed by examining the percentage rel-
ative error (RE%) of the samples at multiple dilutions. The samples
being analyzed at multiple dilutions had a stated nominal concentra-
tion. The effect of dilution on the measured concentrations of anti-
LDL(−) or IC-LDL(−) was examined by four serial dilutions of two
samples and analyzed with the resulting concentration covering the
calibration range. A RE% up to 20% was considered acceptable.
2.6. Stability tests and freeze/thaw cycles
Stability experiments were performed to evaluate the stability of
anti-LDL(−) and IC-LDL(−) under different storage conditions. Ali-
quots of two plasma samples (anti-LDL(−): 3.09 mU/l and 8.20 mU/l;
IC-LDL(−): 9.94 U/l and 5.42 U/l), containing a mixture of protease in-
hibitors and antioxidant, were stored at 4 °C, −20 °C and −80 °C and
were tested for stability every 15 days over a 6 month period. The inﬂu-
ence of freeze/thaw cycles on anti-LDL(−) or IC-LDL(−) was also ex-
amined and aliquots of the 2 samples were subjected to 3 freeze/thaw
cycles. The criteria for stability were deﬁned in terms of the agreement
(RE%b20) between the observed results and a nominal target value.
2.7. Interference
Aliquots of the 2 plasma samples used in stability tests were
spiked with varying concentrations of potential interfering agentssuch as lipids (Lipovenos MCT, Fresenius-Kabi, Campinas, SP, Brazil),
bilirubin (Precibil, Roche Diagnostics, Rotkreuz, Switzerland) and he-
moglobin (Hemoglobin Standard, Labtest, Lagoa Santa, MG, Brazil).
Plasma concentrations of anti-LDL(−) or IC-LDL(−) were determined
before and after spiking in order to gauge the effect of the addition. A
change >20% in the concentration of the spiked samples was consid-
ered as interference.
2.8. Statistical analysis
The values were expressed as a mean±SD. The statistical analysis
was performed using SPSS software ver. 13.0 (Statistical Package for
the Social Sciences Inc., Chicago, IL).
3. Results
3.1. LDL(−) isolation
The isolation and purity of LDL(−) was conﬁrmed by agarose gel
electrophoresis (Fig. 1).
3.2. MAb digestion
The digestion of anti-LDL(−) MAb by papain was conﬁrmed by
SDS-PAGE in the presence of β-mercaptoethanol (Fig. 2).
3.3. ELISA assays development
A typical standard curve for anti-LDL(−), at a range from 0.004 to
0.125 mU/l, is shown in Fig. 3, after 1:400 sample dilution corresponding
to 1.6–50 mU/l. Anti-LDL(−) concentrations were expressed as arbi-
trary mU/l. One arbitrary mU is equivalent to 1 mg of anti-LDL(−).
The working range of the calibration curve for IgG was 0.06–4 U/l
(Fig. 4), after 1:50 sample dilution corresponding to 3–200 U/l. IgG-
LDL(−) concentrations were expressed as arbitrary units of human
IgG per liter (U/l). One arbitrary unit is equivalent to 1 g of IgG.
3.4. Low limits of detection and quantiﬁcation, precision and accuracy
The LOD and LOQ of the anti-LDL(−) ELISA were 0.0028 mU/l and
0.0032 mU/l, respectively. The LOD and LOQ of the IC-LDL(−) ELISA
were 0.02 U/l and 0.03 U/l, respectively. The intra- and inter-assay
1                       2
heavy
light 
chain
chain Fab Fab 
~50 kDa
Papain
~25 kDa
Fc 
Fig. 2. SDS-PAGE under reducing conditions. A: Lane 1: whole 2C7D5F10 MAb, showing two proteins bands, corresponding to heavy chains (~50 kDa) and light chains (~25 kDa).
Lane 2: puriﬁed 2C7D5F10 Fab showing a ~25 kDa double band. The lower band of the doublet corresponds to the light chain and the other to the NH2-terminal half of the cleaved
heavy chain. B: Schematic representation of papain digestion of the MAb into its Fab and Fc antibody fragments.
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LDL(−) ranged from 96.7% to 112.9% and from 92.9% to 118.9%, re-
spectively (Table 2). Although the addition of 0.873 U/l of IC-LDL(−)
in the samples showed a recovery within the required limits (80–
120%), the standard deviation was too high.
3.5. Dilutional linearity
Two plasma samples (A and B) were serially diluted. The RE% for
each diluted sample in the anti-LDL(−) ELISA ranged from 0.43% to
14.74% (Table 3). The RE% for each diluted sample in the IC-LDL(−)3
2
1
A B
Fig. 3. Anti-LDL(−) ELISA. A: Schematic representation of anti-LDL(−) ELISA. Plates were
Goat anti-human IgG conjugated to horseradish peroxidase (3) interacts with IgG anti-LD
curve of anti-LDL(−) ELISA. The data show the mean±standard deviation of triplicate samELISA ranged from 2.3% to 19.3%. The results are summarized in
Table 4.
3.6. Interference
There was no substantial interference on anti-LDL(−) analysis in
samples spiked with lipids up to 800 mg/dl (in terms of triglycerides),
total bilirubin up to 20 mg/dl and hemoglobin up to 250 mg/dl. There
was no substantial interference on IC-LDL(−) analysis in samples
spiked with lipids up to 1000 mg/dl (in terms of triglycerides), total
bilirubin up to 5 mg/dl and hemoglobin up to 500 mg/dl.R2 = 0.996
Ab
so
rb
an
ce
 (4
50
nm
)
Anti-LDL(-)(Log10)
2.0
1.5
1.0
0.5
0.0
-2.5 -2.0 -1.5 -1.0
coated with LDL(−) (1), which binds to anti-LDL(−) autoantibodies from sample (2).
L(−) autoantibodies captured in wells. TMB was used as a chromogen. B: Calibration
ples for each standard concentration.
32
1
BA
R2 = 0.995
Ab
so
rb
an
ce
 (4
50
nm
)
IC-LDL(-)(Log10)
2.0
1.5
1.0
0.5
0.0
1.0 2.51.5 2.0
Fig. 4. IC-LDL(−) ELISA. A: Schematic representation of ELISA for IC-LDL(−) from human plasma. Plates were coated with anti-LDL(−) Fab (1), which binds to immune complexes
of LDL(−) from sample (2). Goat anti-human IgG (Fc speciﬁc) peroxidase conjugate (3) interacts with IC-LDL(−) captured in wells. TMB was used as a chromogen. B: Calibration
curve of IC-LDL(−) ELISA. The data show the mean±standard deviation of triplicate samples for each standard concentration.
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after freezing and freeze/thaw cycles
The results of the stability experiments showed that anti-LDL(−)
and IC-LDL(−) levels from plasma stored at −20 °C and −80 °C
remained practically unchanged for up to 6 months, however, there
was no stability of anti-LDL(−) and IC-LDL(−) in plasma stored at
4 °C. Stability experiments also showed that after a single freeze/
thaw cycle, the concentration of plasma anti-LDL(−) that was stored
at −20 °C decreased by 35.9% and the concentration of plasma anti-
LDL(−) that was stored at−80 °C decreased by 24.8%. There was no
signiﬁcant reduction in the concentration of anti-LDL(−) after subse-
quent freeze/thaw cycles for samples stored at either temperature.
The concentration of plasma IC-LDL(−) that was stored at −20 °C
and−80 °C decreased signiﬁcantly, by 43.9% and 26.4%, respectively,
only after the second freeze/thaw cycle.
4. Discussion
Immunoassays play an important role in the routine diagnosis and
monitoring of diseases in pathological laboratories. The goal of this
study was to develop an ELISA to analyze anti-LDL(−) autoantibodies
and IC-LDL(−) in human plasma. The quantiﬁcation of antibodies
against modiﬁed LDL is a potential tool for the non-invasive diagnosis
of atherosclerotic vascular disease.Table 1
Intra- and inter-assay precision of anti-LDL(−) and IC-LDL(−) ELISAs.
Plasma concentration Intra-assay
mean CV%
Inter-assay
mean CV%
Acceptability
limits %
Anti-LDL(−)
Low (0.006 mU/l) 6.4 16.2 20.0
Medium (0.031 mU/l) 8.3 10.1 15.0
High (0.054 mU/l) 7.3 11.4 15.0
IC-LDL(−)
Low (0.143 U/l) 18.7 18.7 20.0
Medium (0.772 U/l) 13.4 14.3 15.0
High (2.053 U/l) 12.7 14.5 15.0Previous articles have indicated that increased levels of autoanti-
bodies against modiﬁed LDL are associated with future myocardial in-
farction, carotid intima-media-thickness (IMT) and progression of
carotid atherosclerosis [21]. Although autoantibodies to modiﬁed
LDL are linked to atherosclerosis, it has not been fully elucidated if
they are proatherogenic or antiatherogenic. This controversy likely
exists, because of the difﬁculties associated with standardizing the
antigens that are used for detection in analytical assays. The overall
evidence supports the notion that IgG autoantibodies to modiﬁed
LDL are associated with proatherogenic properties and IgM autoanti-
bodies to modiﬁed LDL are associated with atheroprotective proper-
ties [22–25]. Modiﬁed LDL-IgG IC may promote atherosclerosis by
inducing macrophage activation via Fcγ-receptors, which results in
the release of inﬂammatory cytokines and the transformation of mac-
rophages to foam cells [26]. Besides, it was demonstrated that modi-
ﬁed LDL-IgG IC induce expression and secretion of proatherogenic
cytokines by cultured human mast cells [27]. Thus, modiﬁed LDL-
IgG IC may perpetuate a positive feedback loop that ampliﬁes inﬂam-
matory responses. In contrast, IgM antibodies bound to modiﬁed LDL
cannot bind to Fcγ receptors on macrophages and macrophage acti-
vation is prevented [28]. Although there is little data regarding the
role of modiﬁed LDL-IC, some studies have shown that immune com-
plexes are an independent risk factor for the development of a future
myocardial infarction [29] and they are related to the development of
coronary artery calciﬁcation [30] and the progression of internal ca-
rotid IMT in patients with diabetes mellitus [31].Table 2
Recovery of anti-LDL(−) and IC-LDL(−).
Amount added Recoverya
0.008 mU/l of anti-LDL(−), n=2 98.5±6.6
0.013 mU/l of anti-LDL(−), n=2 96.7±2.3
0.024 mU/l of anti-LDL(−), n=2 112.9±1.9
0.030 mU/l of anti-LDL(−), n=2 102.8±3.1
0.163 U/l of IC-LDL(−), n=2 92.9±11.7
0.217 U/l of IC-LDL(−), n=2 112.0±4.1
0.430 U/l of IC-LDL(−), n=2 118.9±0.1
0.873 U/l of IC-LDL(−), n=2 100.7±23.3
a Mean value (%)±standard deviation.
Table 3
Dilutional linearity for anti-LDL(−) in human plasma.
Plasma A B
Nominal
concentration
(mU/l)
6.09 4.63
Dilution 1:100 1:200 1:400 1:800 1:100 1:200 1:400 1:800
Concentration
obtained (mU/l)
6.74 5.85 5.33 5.32 4.66 4.61 4.43 5.31
SD (mU/l) 0.57 0.11 0.06 0.24 0.16 0.30 0.10 0.49
CV (%) 8.50 1.80 1.10 4.40 3.50 6.40 2.40 9.20
RE (%) 10.61 3.97 12.44 12.57 0.57 0.43 4.41 14.74
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tection in blood plasma [8–10] and the results were given as themean
of absorbance values of triplicate samples. Currently, using the anti-
LDL(−) 2C7D5F10 MAb as a standard, we have developed a calibra-
tion curve designed to quantify samples and the results are given as
concentration of anti-LDL(−) [32]. The main components of an
ELISA for autoantibody are the solid phase and the antigen. The spec-
iﬁcity of ELISAs for autoantibody measurement is strongly dependent
on the quality of the antigen used and it is of the utmost importance
that the antigen should have exactly the same sequence, conformation
and post-translationalmodiﬁcations as the human antigen [33]. In this
study, we developed an ELISA for anti-LDL(−) using LDL(−) as anti-
gen, that was isolated from human plasma and not obtained from an
in vitro preparation of modiﬁed LDL. Moreover, for the production of
antigens, puriﬁcation is a crucial step. If a contaminant antigen is pre-
sent during the puriﬁcation process, cross-reactivity may occur later
in the ELISA assay, which can compromise its speciﬁcity. The present
ELISA for anti-LDL(−) uses LDL(−) that has been puriﬁed by chroma-
tography, thus ensuring the quality of the assay.
Immune complex formation in vivo may lead to spurious low
levels of free anti-modiﬁed LDL antibody. Levels of antibody formed
against an antigen are highly variable, depending on the individual
variations in the immune response and the avidity of the antibody
to the respective antigen. Thus, the measurement of free circulating
autoantibodies depends not only on the antibody response but also
on antibody avidity and on the amount of antigen present in the cir-
culation [34]. Patients who produce antibodies of higher avidity may
have higher levels of circulating and potentially pathogenic IC and
lower levels of free, circulating modiﬁed LDL antibodies. Immune
complex quantiﬁcation is usually performed using 2 techniques: pre-
cipitation with polyethylene glycol (PEG), which is the oldest test for
circulating IC [35,36] and capture ELISA [37,38]. The ELISA we develop
to quantify IC-LDL(−) has the advantage of using an anti-LDL(−) Fab
that is coated on the plate and an anti-Fc-IgG detection antibody.
Using this pair of antibodies, we eliminated the possibility of nonspe-
ciﬁc binding interactions between the antibodies, which decrease the
background noise.
Several groups have dedicated considerable effort to developing
assays for antibodies that react with copper-oxidized LDL and/or
with malondialdehyde-modiﬁed LDL [39]. However, the extent toTable 4
Dilutional linearity for IC-LDL(−) in human plasma.
Plasma A B
Nominal
concentration
(U/l)
11.42 28.86
Dilution 1:12.5 1:25 1:50 1:100 1:12.5 1:25 1:50 1:100
Concentration
obtained (U/l)
13.60 12.42 11.13 9.21 24.85 29.53 29.93 23.94
SD (U/l) 0.99 0.94 0.28 0.71 1.82 1.73 0.98 1.77
CV (%) 7.30 7.60 2.50 7.70 7.30 5.90 3.30 7.40
RE (%) 19.10 8.70 2.50 19.30 13.90 2.30 3.70 17.10which in vitromodiﬁcation of LDL reproduces the epitopes generated
during in vivomodiﬁcation remains unclear. As mentioned above, the
immunoassays developed in our study have the advantage of detect-
ing autoantibodies against an in vivo-derived minimally modiﬁed
subfraction of LDL.
ELISA assay validation showed intra- and inter-assay precision and
recovery within the required limits for immunoassays [40]. The pres-
ence of lipids, bilirubin and hemoglobin in the samples did not seriously
impact the assay. Plasma stored at −20 °C and −80 °C remained
unchanged for up to 6 months, however, freeze/thaw cycles of the sam-
ples decreased the plate reading in the assay.
In conclusion, both ELISAs were validated for the intended appli-
cation and can be used for clinical and biochemical research to gener-
ate new information about atherosclerosis and its mechanisms. In
addition, these assays will allow a comprehensive evaluation of the
importance of bound or free autoantibodies against LDL(−) in the
atherosclerosis.
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